Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665444 · ClinicalTrials.gov registry record · NA
Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder
A NA study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00665444 is a NA study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 3 participants.
The verdict
NCT00665444, a NA study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The proposed study is a non-randomized, open label trial that will examine the potential to reduce metabolic risk factors in patients with bipolar I disorder and improve psychiatric and functional outcomes. To accomplish our objective, we plan to conduct a 5-month intervention of 50 obese or overweight adults diagnosed with bipolar disorder. The study will be divided in three steps: Screening, Baseline Period (cross taper to aripiprazole, up to 2 months in duration), Months 1-3 (continued aripiprazole treatment). Subjects will be assessed and meet with their study psychiatrist at least bi-monthly throughout their participation, more frequently when clinically necessary (e.g. during medication tapering or if manic/depressive symptoms emerge). Brief clinical assessments will be conducted at each visit. More thorough assessments will be conducted at Baseline, Week 2, and Month 3.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00665444
The ClinicalTrials.gov registry entry for NCT00665444 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00665444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00665444 about?
NCT00665444 is a clinical study titled "Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder". The proposed study is a non-randomized, open label trial that will examine the potential to reduce metabolic risk factors in patients with bipolar I disorder and improve psychiatric and functional outcomes. To accomplish our objective, we plan to conduct a 5-month intervention of 50 obese or overwei...
What is the current status of trial NCT00665444?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2008-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00665444?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00665444?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.